<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Oncol.</journal-id>
<journal-title>Frontiers in Oncology</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Oncol.</abbrev-journal-title>
<issn pub-type="epub">2234-943X</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fonc.2023.1119915</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oncology</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>A bibliometric analysis based on Web of Science from 2012 to 2021: Current situation, hot spots, and global trends of medullary thyroid carcinoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Ruyin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/2092165"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Yingjiao</given-names>
</name>
<xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1879924"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhao</surname>
<given-names>Zirui</given-names>
</name>
<xref ref-type="aff" rid="aff3">
<sup>3</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Li</surname>
<given-names>Xiaobin</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Liu</surname>
<given-names>Ziwen</given-names>
</name>
<xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref>
<xref ref-type="author-notes" rid="fn001">
<sup>*</sup>
</xref>
<xref ref-type="author-notes" rid="fn003">
<sup>&#x2020;</sup>
</xref>
<uri xlink:href="https://loop.frontiersin.org/people/1694103"/>
</contrib>
</contrib-group>
<aff id="aff1">
<sup>1</sup>
<institution>Department of General Surgery, Peking Union Medical College, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences</institution>, <addr-line>Beijing</addr-line>, <country>China</country>
</aff>
<aff id="aff2">
<sup>2</sup>
<institution>Department of Breast Surgery, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences</institution>, <addr-line>Beijing</addr-line>, <country>China</country>
</aff>
<aff id="aff3">
<sup>3</sup>
<institution>Department of Neurology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences</institution>, <addr-line>Beijing</addr-line>, <country>China</country>
</aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Guy Andry, Universit&#xe9; libre de Bruxelles, Belgium</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Ying-Hsia Chu, ACT Genomics Co., LTD, Taiwan; Valeria Mazzi, Universit&#xe0; degli Studi di Pisa, Italy</p>
</fn>
<fn fn-type="corresp" id="fn001">
<p>*Correspondence: Xiaobin Li, <email xlink:href="mailto:xbli2008@sina.com">xbli2008@sina.com</email>; Ziwen Liu, <email xlink:href="mailto:liuziwen@pumch.cn">liuziwen@pumch.cn</email>
</p>
</fn>
<fn fn-type="equal" id="fn003">
<p>&#x2020;These authors have contributed equally to this work</p>
</fn>
<fn fn-type="other" id="fn002">
<p>This article was submitted to Head and Neck Cancer, a section of the journal Frontiers in Oncology</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>07</day>
<month>03</month>
<year>2023</year>
</pub-date>
<pub-date pub-type="collection">
<year>2023</year>
</pub-date>
<volume>13</volume>
<elocation-id>1119915</elocation-id>
<history>
<date date-type="received">
<day>09</day>
<month>12</month>
<year>2022</year>
</date>
<date date-type="accepted">
<day>22</day>
<month>02</month>
<year>2023</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#xa9; 2023 Li, Wang, Zhao, Li and Liu</copyright-statement>
<copyright-year>2023</copyright-year>
<copyright-holder>Li, Wang, Zhao, Li and Liu</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec>
<title>Background</title>
<p>Medullary thyroid carcinoma (MTC) is a special type of thyroid carcinoma derived from the C cell of the thyroid gland. Because of the poor prognosis of MTC, a large number of studies on MTC have been conducted in the last 10 years. To better comprehend, it is necessary to clarify and define the dominant countries, organizations, core journals, important authors, and their cumulative research contributions, as well as the cooperative relationships between them.</p>
</sec>
<sec>
<title>Method</title>
<p>English publications with article type article or review about MTC from January 2012 to December 2021 was retrieved from Web of Science core collection, and VOSviewer, CiteSpace, and Microsoft Excel were applied for bibliometric study.</p>
</sec>
<sec>
<title>Result</title>
<p>A total of 1208 articles and reviews were included in this study. The 1208 papers were written by 6364 authors from 1734 organizations in 67 countries, published in 408 journals, and cited 24118 references from 3562 journals. The number of publications was essentially flat from 2012-2021, with the largest proportion of publications coming from the U.S., followed by Italy and China. Thyroid was the most productive journal, and Journal of clinical endocrinology &amp; metabolism was the most cited journal. University of Texas MD Anderson Cancer Center was the most productive institution and Luca Giovanella, was the most productive author. Diagnostic tools, surgical treatment, non-surgical treatment, genetics and relationship with other endocrine diseases were the main research interests in this field. Prognosis has been a cutting-edge topic since 2017.</p>
</sec>
<sec>
<title>Conclusion</title>
<p>As a thyroid cancer with poor prognosis, MTC has received continuous attention in recent years. Current MTC studies mainly focused on disease intervention, mechanism research and prognosis. The main point of this study is to provide an overview of the development process and hot spots of MTC in the last decade. These might provide ideas for further research in the MTC field.</p>
</sec>
</abstract>
<kwd-group>
<kwd>medullary thyroid carcinoma</kwd>
<kwd>Web of Science</kwd>
<kwd>VOSviewer</kwd>
<kwd>trends</kwd>
<kwd>bibliometric analysis</kwd>
</kwd-group>
<counts>
<fig-count count="6"/>
<table-count count="6"/>
<equation-count count="0"/>
<ref-count count="29"/>
<page-count count="9"/>
<word-count count="4122"/>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Thyroid cancer is the most common endocrine malignant tumor. According to the histopathological type, it can be divided into medullary thyroid carcinoma (MTC), anaplastic thyroid carcinoma and differentiated thyroid cancer(DTC), which includes papillary thyroid cancer, follicular thyroid cancer (<xref ref-type="bibr" rid="B1">1</xref>). MTC is a special type of thyroid cancer derived from the C cell of the thyroid gland, with elevated plasma calcitonin and carcinoembryonic antigen, accounting for about 2% of all thyroid carcinomas (<xref ref-type="bibr" rid="B2">2</xref>). Depending on the clinical symptoms of MTC, it can be classified as hereditary (75%) and sporadic (25%) (<xref ref-type="bibr" rid="B3">3</xref>). Compared with DTC, MTC is more likely to find local lymph nodes metastasis, and the overall 10-year survival rate of MTC ranges 61-76% (<xref ref-type="bibr" rid="B4">4</xref>). Total thyroidectomy and dissection with or without cervical lymph node compartments is standard treatment for patients with MTC (<xref ref-type="bibr" rid="B5">5</xref>). Recently, as a poorly prognosed thyroid carcinoma, a large number of studies have been conducted on MTC.</p>
<p>Bibliometric analysis is an effective tool. By summarizing and analyzing the data of countries and regions, journals, authors, keywords, citations, bibliometric analysis can visually reveal the developing process, current status and hotspots of researches in one field as well as predict the global trends in the future (<xref ref-type="bibr" rid="B6">6</xref>, <xref ref-type="bibr" rid="B7">7</xref>).</p>
<p>Recently, the application of bibliometric analysis in the field of thyroid research is focused on diseases such as papillary thyroid cancer (<xref ref-type="bibr" rid="B8">8</xref>) and anaplastic thyroid cancer (<xref ref-type="bibr" rid="B9">9</xref>). To our acknowledge, there is no bibliometric analysis on MTC. Then, we searched &#x201c;medullary thyroid carcinoma OR thyroid AND carcinoma, medullary&#x201d; and &#x201c;Bibliometrics OR Bibliometric&#x201d; on Web of Science and PubMed, and no relevant papers were found. As the first bibliometric analysis on MTC, this study aims to use bibliometric methods to reveal the development process, current status, hotspots and predict global future trends in the field of MTC research.</p>
</sec>
<sec id="s2" sec-type="materials|methods">
<title>Materials and methods</title>
<sec id="s2_1">
<title>Data source</title>
<p>Web Of Science (<ext-link ext-link-type="uri" xlink:href="https://access.clarivate.com">https://access.clarivate.com</ext-link>) is a database of high-quality articles covering multiple fields, most commonly used for bibliometric analysis (<xref ref-type="bibr" rid="B10">10</xref>). Compared to PubMed and Scopus, Web of Science has a greater reach, higher quality literature, and easier access to citation information for articles (<xref ref-type="bibr" rid="B11">11</xref>). In order to make the target article information more accurate and comprehensive, this research chose Web of Science Core Collection as data source and set the citation indexes as Science Citation Index Expanded and Social Sciences Citation Index.</p>
<p>Further, since the corresponding search strategy for MTC in the Medical Subject Headings Database (MeSH) is &#x201c;Thyroid AND Carcinoma, medullary&#x201d;, we determined the subject term search formula as &#x201c;TS=Thyroid AND Carcinoma, medullary &#x201c;, and set the time span from January 1, 2012 to December 31, 2021, the article type as &#x201c;Article&#x201d; or &#x201c;Review&#x201d;, and the language as &#x201c;English&#x201d;. Ultimately, the full search formula for obtaining data is as follows.((TS=(Thyroid AND Carcinoma, medullary)) AND LA=(English)) AND DT=(Article OR Review). (This search was completed on November 21, 2022).</p>
<p>Finally, a total of 2056 articles were retrieved. After browsing article abstracts, we removed 851 articles with large deviations from the topic and 1 duplication, resulting in a total of 1208 valid articles, including 947articles and 265 reviews. The 1208 papers used in this study were authored by 6364 authors from 1734 organizations in 67 countries. And they were published in 408 journals and 24118 references were cited from 3562 journals.</p>
</sec>
<sec id="s2_2">
<title>Method</title>
<p>VOSviewer and CitesSpace are bibliometric softwares and both pay special attention to the graphical representation of bibliometric maps. VOSviewer applies probabilistic-based data normalization methods to produce bibliometric maps, including network visualization, overlay visualization and density visualization. The main function of VOSviewer is to cluster data and present co-occurrence relationships between data, usually used to analyze authors, countries, journals, citations, and keywords. The significant advantage of VOSviewer is that the map is beautiful and easy to understand (<xref ref-type="bibr" rid="B12">12</xref>). CiteSpace applies a set theory-based data normalization approach to produce bibliometric maps. The main functions of CiteSpace and VOSviewer are basically the same. However CiteSpace is often used to analyze keywords. The advantage of CiteSpace is that a timeline view of the data (Timeline) and the burst words can be obtained, which allows a clear presentation of the research development process and frontiers in a field (<xref ref-type="bibr" rid="B13">13</xref>).</p>
<p>In this study, VOSviewer (Version 1.6.18), CitesSpace (Version 6.1.R4), and Microsoft Excel were applied to analyze and map the distribution of publications, countries, institutions, authors, journals, keywords and citations of the retrieved 1208 articles. The search strategy, data screening and bibliometric analysis steps can be found in <xref ref-type="fig" rid="f1">
<bold>Figure&#xa0;1</bold>
</xref>.</p>
<fig id="f1" position="float">
<label>Figure&#xa0;1</label>
<caption>
<p>Search strategy, data screening and bibliometric analysis steps.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1119915-g001.tif"/>
</fig>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec id="s3_1">
<title>Distribution of publications by year</title>
<p>To better understand the current status of publications in the field of MTC, this study analyzed the distribution of publications by year from 2012 to 2021.Time trend of the publications on MTC research can be seen in <xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>. The annual number of publications in the field of MTC had been stable at 105 and above in the past 10 years. Annual publication volume peaked at 140 articles in 2020 and 2021.</p>
<fig id="f2" position="float">
<label>Figure&#xa0;2</label>
<caption>
<p>Time trend of the publications on MTC.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1119915-g002.tif"/>
</fig>
</sec>
<sec id="s3_2">
<title>Countries</title>
<p>To clarify the contribution of different countries to research on MTC, this study conducted an bibliometric analysis of the 67 countries involved. Setting the minimum number of national publications at 42 through VOSViewer, we obtained the top 10 countries in terms of the number of publications (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>) and visualized the cooperation between the top 10 countries (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>).</p>
<table-wrap id="T1" position="float">
<label>Table&#xa0;1</label>
<caption>
<p>Top 10 countries in the MTC research field.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="center">Country</th>
<th valign="middle" align="center">Publications</th>
<th valign="middle" align="center">Citations</th>
<th valign="middle" align="center">Average Citation/Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">Usa</td>
<td valign="middle" align="left">299</td>
<td valign="middle" align="left">7163</td>
<td valign="middle" align="left">23.96</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">Italy</td>
<td valign="middle" align="left">188</td>
<td valign="middle" align="left">4593</td>
<td valign="middle" align="left">24.43</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">China</td>
<td valign="middle" align="left">172</td>
<td valign="middle" align="left">1652</td>
<td valign="middle" align="left">9.60</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">Germany</td>
<td valign="middle" align="left">69</td>
<td valign="middle" align="left">2441</td>
<td valign="middle" align="left">35.38</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">France</td>
<td valign="middle" align="left">56</td>
<td valign="middle" align="left">2090</td>
<td valign="middle" align="left">37.32</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">Spain</td>
<td valign="middle" align="left">52</td>
<td valign="middle" align="left">735</td>
<td valign="middle" align="left">14.13</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">Japan</td>
<td valign="middle" align="left">49</td>
<td valign="middle" align="left">585</td>
<td valign="middle" align="left">11.94</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">South korea</td>
<td valign="middle" align="left">49</td>
<td valign="middle" align="left">556</td>
<td valign="middle" align="left">11.35</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Switzerland</td>
<td valign="middle" align="left">45</td>
<td valign="middle" align="left">996</td>
<td valign="middle" align="left">22.13</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Brazil</td>
<td valign="middle" align="left">43</td>
<td valign="middle" align="left">537</td>
<td valign="middle" align="left">12.49</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="f3" position="float">
<label>Figure&#xa0;3</label>
<caption>
<p>Co-occurrence of the 10 most productive countries.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1119915-g003.tif"/>
</fig>
<p>
<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref> showed that the top three productive countries were the United States, Italy and China. The top cited countries were the United States, Italy and Germany. And the three countries with the highest average citation rate were France, Germany and Italy.</p>
<p>In <xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>, larger nodes suggested more postings, and thicker lines between two countries suggested more cooperation. From this picture, we got the following information:1. The three countries that cooperated the most with other countries were Italy, the United States and China.2. Italy mainly cooperated with European countries, while the United States cooperated with all countries, and China cooperated with all countries except Switzerland. 3. Italy and the United States had much more international cooperation than China.</p>
</sec>
<sec id="s3_3">
<title>Organizations</title>
<p>According to VOSviewer analysis, 1734 different organizations were involved in the research worldwide. Setting the minimum number of articles issued by the institution at 17, the top 10 organizations ranked by document numbers were shown in <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref> with total citations and countries. As could be seen from <xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>, the top three institutions in terms of number of publications were University of Texas MD Anderson Cancer Center, University of Pisa, University of Padua. University of Texas MD Anderson Cancer Center had the highest number of citations. Moreover, four of the 10 most productive institutions were from Italy.</p>
<table-wrap id="T2" position="float">
<label>Table&#xa0;2</label>
<caption>
<p>Top 10 organizations in the MTC research field.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Organizations</th>
<th valign="middle" align="center">Publications</th>
<th valign="middle" align="center">Citations</th>
<th valign="top" align="left">Country</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">University of Texas MD Anderson Cancer Center</td>
<td valign="middle" align="left">38</td>
<td valign="middle" align="left">2273</td>
<td valign="middle" align="left">USA</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">University of Pisa</td>
<td valign="middle" align="left">35</td>
<td valign="middle" align="left">1830</td>
<td valign="middle" align="left">Italy</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">University of Padua</td>
<td valign="middle" align="left">26</td>
<td valign="middle" align="left">375</td>
<td valign="middle" align="left">Italy</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">University of Naples Federico II</td>
<td valign="middle" align="left">20</td>
<td valign="middle" align="left">1607</td>
<td valign="middle" align="left">Italy</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">Sapienza University of Rome</td>
<td valign="middle" align="left">20</td>
<td valign="middle" align="left">606</td>
<td valign="middle" align="left">Italy</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">Memorial Sloan-Kettering Cancer Center</td>
<td valign="middle" align="left">19</td>
<td valign="middle" align="left">1465</td>
<td valign="middle" align="left">USA</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">Zhejiang university</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">257</td>
<td valign="middle" align="left">China</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">KUMA hospital</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">235</td>
<td valign="middle" align="left">Japan</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Oncology Institute of Southern Switzerland</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">471</td>
<td valign="middle" align="left">Switzerland</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Radboud University Nijmegen</td>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">355</td>
<td valign="middle" align="left">Netherlands</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_4">
<title>Authors</title>
<p>A total of 6364 authors were further analyzed using the VOSViewer. The top ten productive authors could be obtained by setting the minimum number of publications to 11(<xref ref-type="table" rid="T3">
<bold>Table&#xa0;3</bold>
</xref>). Among these productive authors, the most productive was Luca Giovanella from New Zealand. From January 1, 2012 to December 31, 20221, he had published 24 publications with 575 citations and average citations of 23.96.The second most published and most cited author was Rossella Elisei from the University of Pisa, Italy. From January 1, 2012 to December 31, 20221, he had published 18 publications with 1,351 citations and average citations of 75.06. The two authors with the most average citation were Henning Dralle and Andreas Machens. They were from the same institution and had co-authored 13 articles with 1315 citations and average citations of 100.46.</p>
<table-wrap id="T3" position="float">
<label>Table&#xa0;3</label>
<caption>
<p>The most important authors in the MTC research field.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Author</th>
<th valign="middle" align="center">Documents</th>
<th valign="middle" align="center">Citations</th>
<th valign="middle" align="center">Average Citation/Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">Luca Giovanella</td>
<td valign="middle" align="left">24</td>
<td valign="middle" align="left">575</td>
<td valign="middle" align="left">23.96</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">Rossella Elisei</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">1351</td>
<td valign="middle" align="left">75.06</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">Pierpaolo Trimboli</td>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">473</td>
<td valign="middle" align="left">29.56</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">Alessandro Antonelli</td>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">334</td>
<td valign="middle" align="left">23.86</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">Henning Dralle</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">1315</td>
<td valign="middle" align="left">100.46</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">Andreas Machens</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">1315</td>
<td valign="middle" align="left">100.46</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">Cristina Romei</td>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">221</td>
<td valign="middle" align="left">17</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Poupak Fallahi</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">284</td>
<td valign="middle" align="left">23.67</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Caterina Mian</td>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">186</td>
<td valign="middle" align="left">15.5</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Barbara Jarz&#x105;b</td>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">126</td>
<td valign="middle" align="left">11.45</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_5">
<title>Journals</title>
<p>Bradford proposed that the ratio of core, related and peripheral journals in a field for a given time period is 1:<italic>n</italic>:<italic>n</italic>
<sup>2</sup> (<xref ref-type="bibr" rid="B14">14</xref>). There were 408 journals involved in this study, so the number of the core journal was about 8. The top 8 productive journals could be obtained by setting the minimum number of publications to 18 through VOSviewer(<xref ref-type="table" rid="T4">
<bold>Table&#xa0;4</bold>
</xref>). And the main directions of these journals were cancers and diseases derived from the thyroid, endocrine system, head and neck. Thyroid, Endocrine, and Diagnostic cytopathology were the top three journals with the highest publication. The journal with the most average citations was Journal of clinical endocrinology &amp; metabolism, which published 19 MTC-related articles with 1,029 citations and 54.16 average citations. It was followed by Thyroid with 41 publications and 1,889 citations, with an average citation of 46.07.</p>
<table-wrap id="T4" position="float">
<label>Table&#xa0;4</label>
<caption>
<p>Top 8 journals in the MTC research field.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Source</th>
<th valign="middle" align="center">Publications</th>
<th valign="middle" align="center">Citations</th>
<th valign="middle" align="center">Average Citation/Publication</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">Thyroid</td>
<td valign="middle" align="left">41</td>
<td valign="middle" align="left">1889</td>
<td valign="middle" align="left">46.07</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">Endocrine</td>
<td valign="middle" align="left">33</td>
<td valign="middle" align="left">355</td>
<td valign="middle" align="left">10.76</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">Diagnostic cytopathology</td>
<td valign="middle" align="left">31</td>
<td valign="middle" align="left">299</td>
<td valign="middle" align="left">9.65</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">Endocrine-related cancer</td>
<td valign="middle" align="left">30</td>
<td valign="middle" align="left">771</td>
<td valign="middle" align="left">25.7</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">Endocrine pathology</td>
<td valign="middle" align="left">29</td>
<td valign="middle" align="left">316</td>
<td valign="middle" align="left">10.90</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">Frontiers in endocrinology</td>
<td valign="middle" align="left">19</td>
<td valign="middle" align="left">143</td>
<td valign="middle" align="left">7.53</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">Journal of clinical endocrinology &amp; metabolism</td>
<td valign="middle" align="left">19</td>
<td valign="middle" align="left">1029</td>
<td valign="middle" align="left">54.16</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Head and neck-journal for the sciences and specialties of the head and neck</td>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">229</td>
<td valign="middle" align="left">12.72</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec id="s3_6">
<title>Keywords</title>
<p>A total of 3964 keywords were extracted from 1208 articles. The relationship between the 300 most frequent keywords were visualized by VOSViewer as follows (<xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>). According to <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref>, we found that all the keywords centered around MTC. These keywords were divided into 4 main clusters: non-surgical treatment (red cluster), surgical treatment (green cluster), genetic changes and correlation with other endocrine diseases (blue cluster), diagnosis (yellow and purple clusters), which included nodal ultrasound and biopsy, and also PET/CT for MTC. The minimum number of occurrences of a key word was set to 64 in VOSViewer, and the top 20 keywords were selected and listed in <xref ref-type="table" rid="T5">
<bold>Table&#xa0;5</bold>
</xref>. The top three keywords were medullary thyroid carcinoma, carcinoma, and prognosis.</p>
<fig id="f4" position="float">
<label>Figure&#xa0;4</label>
<caption>
<p>Co-occurrence of the keywords.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1119915-g004.tif"/>
</fig>
<table-wrap id="T5" position="float">
<label>Table&#xa0;5</label>
<caption>
<p>The top 20 keywords in the MTC research field.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Source</th>
<th valign="middle" align="center">Publications</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">medullary thyroid carcinoma</td>
<td valign="middle" align="left">1001</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">carcinoma</td>
<td valign="middle" align="left">326</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">prognosis</td>
<td valign="middle" align="left">273</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">ret gene</td>
<td valign="middle" align="left">268</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">management</td>
<td valign="middle" align="left">267</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">calcitonin</td>
<td valign="middle" align="left">242</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">gene mutation</td>
<td valign="middle" align="left">229</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">guideline</td>
<td valign="middle" align="left">178</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">diagnosis</td>
<td valign="middle" align="left">163</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">papillary thyroid carcinoma</td>
<td valign="middle" align="left">157</td>
</tr>
<tr>
<td valign="middle" align="left">11</td>
<td valign="middle" align="left">expression</td>
<td valign="middle" align="left">109</td>
</tr>
<tr>
<td valign="middle" align="left">12</td>
<td valign="middle" align="left">endocrine neoplasia type-2</td>
<td valign="middle" align="left">104</td>
</tr>
<tr>
<td valign="middle" align="left">13</td>
<td valign="middle" align="left">thyroid nodule</td>
<td valign="middle" align="left">95</td>
</tr>
<tr>
<td valign="middle" align="left">14</td>
<td valign="middle" align="left">protooncogene</td>
<td valign="middle" align="left">94</td>
</tr>
<tr>
<td valign="middle" align="left">15</td>
<td valign="middle" align="left">thyroid</td>
<td valign="middle" align="left">90</td>
</tr>
<tr>
<td valign="middle" align="left">16</td>
<td valign="middle" align="left">vandetanib</td>
<td valign="middle" align="left">81</td>
</tr>
<tr>
<td valign="middle" align="left">17</td>
<td valign="middle" align="left">phase-ii trial</td>
<td valign="middle" align="left">74</td>
</tr>
<tr>
<td valign="middle" align="left">18</td>
<td valign="middle" align="left">pheochromocytoma</td>
<td valign="middle" align="left">70</td>
</tr>
<tr>
<td valign="middle" align="left">19</td>
<td valign="middle" align="left">tyrosine kinase inhibitor</td>
<td valign="middle" align="left">65</td>
</tr>
<tr>
<td valign="middle" align="left">20</td>
<td valign="middle" align="left">fine-needle-aspiration</td>
<td valign="middle" align="left">64</td>
</tr>
</tbody>
</table>
</table-wrap>
<p>Burst words can reflect the hot spots of research in a field at different times. Citespace was applied to analyze 3964 keywords contained in 1208 articles for burst words, and a total of 43 burst words were filtered. Excluding the 27 burst words with strength less than 3 and 4 non-informative terms, a total of 12 valid burst words were captured (<xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref>). In the early period from 2012 to 2021, hot spots in MTC research included phase II clinical trials (began in 2012 ended in 2015), targeted therapies (began in 2012 ended in 2015), epithelial growth factor (began in 2012 ended in 2015), <italic>BRAF</italic> mutations (began in 2012 ended in 2013), while later research hot spots included sorafenib(began in 2013ended in 2015),increasing incidence (began in 2013 ended in 2015), receptor (began in 2014 ended in 2015), breast cancer (began in 2015 ended in 2017), protein (began in 2015 ended in 2016), disease phenotype (began in 2016 ended in 2019), expression (began in 2016 ended in 2017). Since 2017, the burst word outcome has become a new research hotspot.</p>
<fig id="f5" position="float">
<label>Figure&#xa0;5</label>
<caption>
<p>The top 12 burst words.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1119915-g005.tif"/>
</fig>
</sec>
<sec id="s3_7">
<title>Citations</title>
<p>VOSViewer was used to filter the top 10 cited articles among 1208 articles, and the minimum number of citations was set to 100 to get <xref ref-type="table" rid="T6">
<bold>Table&#xa0;6</bold>
</xref>.The majority of the 10 highly cited articles were review articles, mostly on guidelines and targeted therapies for MTC. Applying VOSviewer to filter 24118 citations from 3562 journals and setting the mini mum number of citations to 160, the top 50 cited journals were obtained and their co-citation relationships were shown in <xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref>.It revealed a strong collaboration between journals in the field of MTC research, and the top three cited journals were Journal of clinical endocrinology &amp; metabolism, Thyroid, and Journal of clinical oncology. The co-citation network of the journal included four clusters, including endocrine-related and surgery (red cluster), pathology (blue cluster), and oncology, molecular direction (green and yellow clusters).</p>
<table-wrap id="T6" position="float">
<label>Table&#xa0;6</label>
<caption>
<p>Top 10 highly cited documents in the MTC research field.</p>
</caption>
<table frame="hsides">
<thead>
<tr>
<th valign="middle" align="left">Rank</th>
<th valign="middle" align="left">Tittle</th>
<th valign="middle" align="left">Author</th>
<th valign="middle" align="left">Journal</th>
<th valign="middle" align="left">Citations</th>
<th valign="top" align="left">Year</th>
</tr>
</thead>
<tbody>
<tr>
<td valign="middle" align="left">1</td>
<td valign="middle" align="left">Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma</td>
<td valign="middle" align="left">Samuel A. WellsJr</td>
<td valign="middle" align="left">thyroid</td>
<td valign="middle" align="left">1033</td>
<td valign="middle" align="left">2015</td>
</tr>
<tr>
<td valign="middle" align="left">2</td>
<td valign="middle" align="left">Targeted Next-Generation Sequencing Panel (ThyroSeq) for Detection of Mutations in Thyroid Cancer</td>
<td valign="middle" align="left">Marina N.Nikiforova</td>
<td valign="middle" align="left">The Journal of Clinical Endocrinology &amp; Metabolism</td>
<td valign="middle" align="left">316</td>
<td valign="middle" align="left">2013</td>
</tr>
<tr>
<td valign="middle" align="left">3</td>
<td valign="middle" align="left">Multiple Endocrine Neoplasia Type 2 and Familial Medullary Thyroid Carcinoma: An Update</td>
<td valign="middle" align="left">Samuel A.WellsJr</td>
<td valign="middle" align="left">
<italic>The Journal of Clinical Endocrinology &amp; Metabolism</italic>
</td>
<td valign="middle" align="left">188</td>
<td valign="top" align="left">2013</td>
</tr>
<tr>
<td valign="middle" align="left">4</td>
<td valign="middle" align="left">German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors</td>
<td valign="middle" align="left">Henning Dralle</td>
<td valign="middle" align="left">Langenbeck&#x2019;s Archives of Surgery</td>
<td valign="middle" align="left">144</td>
<td valign="top" align="left">2013</td>
</tr>
<tr>
<td valign="middle" align="left">5</td>
<td valign="middle" align="left">NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018</td>
<td valign="middle" align="left">Robert I Haddad</td>
<td valign="middle" align="left">Journal of the National Comprehensive Cancer Network: JNCCN</td>
<td valign="middle" align="left">136</td>
<td valign="top" align="left">2018</td>
</tr>
<tr>
<td valign="middle" align="left">6</td>
<td valign="middle" align="left">Thyroid carcinoma, version 2.2014</td>
<td valign="middle" align="left">R Michael Tuttle</td>
<td valign="middle" align="left">Journal of the National Comprehensive Cancer Network: JNCCN</td>
<td valign="middle" align="left">114</td>
<td valign="top" align="left">2014</td>
</tr>
<tr>
<td valign="middle" align="left">7</td>
<td valign="middle" align="left">The Role of Cdk5 in Neuroendocrine Thyroid Cancer</td>
<td valign="middle" align="left">Karine Pozo</td>
<td valign="middle" align="left">Cancer Cell</td>
<td valign="middle" align="left">112</td>
<td valign="top" align="left">2016</td>
</tr>
<tr>
<td valign="middle" align="left">8</td>
<td valign="middle" align="left">Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma</td>
<td valign="middle" align="left">M. Schlumberger</td>
<td valign="middle" align="left">Annals of oncology: official journal of the European Society for Medical Oncology</td>
<td valign="middle" align="left">106</td>
<td valign="top" align="left">2017</td>
</tr>
<tr>
<td valign="middle" align="left">9</td>
<td valign="middle" align="left">Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond</td>
<td valign="middle" align="left">Maria E Cabanillas</td>
<td valign="middle" align="left">Endocrine reviews</td>
<td valign="middle" align="left">104</td>
<td valign="top" align="left">2019</td>
</tr>
<tr>
<td valign="middle" align="left">10</td>
<td valign="middle" align="left">Lenvatinib: Role in thyroid cancer and other solid tumors</td>
<td valign="middle" align="left">Maria E Cabanillas</td>
<td valign="middle" align="left">Cancer treatment reviews</td>
<td valign="middle" align="left">104</td>
<td valign="top" align="left">2016</td>
</tr>
</tbody>
</table>
</table-wrap>
<fig id="f6" position="float">
<label>Figure&#xa0;6</label>
<caption>
<p>Co-occurrence of the top 50 cited journals.</p>
</caption>
<graphic mimetype="image" mime-subtype="tiff" xlink:href="fonc-13-1119915-g006.tif"/>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>MTC is a rare type of thyroid cancer with a poor prognosis. In recent years, researchers have conducted numerous studies on the pathogenesis and treatment of MTC in order to improve the prognosis of MTC patients, while no bibliometric article on MTC has been published worldwide. This paper is the first bibliometric analysis on the field of MTC research, visualizing 1208 publications in the field of MTC from 2012 to 2021 in terms of trends in publication, most scientifically productive countries, organizations, journals, authors, keywords and citations. This research reveals the development process, current research status and hotspots in the field of MTC from 2012 to 2021, and predicts global trends in this field.</p>
<p>From 2012 to 2021, the average annual number of articles in the MTC field was stable above 105, which reached a peak of 140 articles per year in 2020 and 2021 (<xref ref-type="fig" rid="f2">
<bold>Figure&#xa0;2</bold>
</xref>), indicating that MTC had been a hot pot and received increasing attention in recent years.</p>
<p>The top ten most productive countries were concentrated in the Americas, Asia and Europe, which proved that the publication situation in this research area was not evenly distributed at the world level. And the United States and Italy were leading in publication energy and citations, further revealing the dominance of the United States and Italy in the field of MTC research and the high quality of publications (<xref ref-type="table" rid="T1">
<bold>Table&#xa0;1</bold>
</xref>). The partnership mapping of the top ten countries of publication showed that the United States, Italy, and China, which had the highest number of publications, had more cooperation with other countries, suggesting frequent cooperation among the most productive countries in MTC research and a good international exchange pattern (<xref ref-type="fig" rid="f3">
<bold>Figure&#xa0;3</bold>
</xref>).</p>
<p>An analysis of the organization of the literature is key to identifying the core organizations in the field. The top three publishers among the 1,734 institutions covered in this article were University of Texas MD Anderson Cancer Center, University of Pisa, and University of Padua, all from the United States or Italy. In addition, the top ten organizations publishing papers were from the United States and Italy, accounting for six of them. This result was consistent with the results of the national bibliometric analysis, proving once again that the United States and Italy were located at the center of this research field (<xref ref-type="table" rid="T2">
<bold>Table&#xa0;2</bold>
</xref>).</p>
<p>Analysis of the authors of the papers reveals the representative scholars and core research strengths in the field of research. The top author in the field of MTC in the last 10 years was Luca Giovanella, with 24 publications, mainly devoted to the study of MTC diagnosis (<xref ref-type="bibr" rid="B15">15</xref>), including the evaluation of the diagnostic efficacy of fine needle aspiration cytology (<xref ref-type="bibr" rid="B16">16</xref>) and calcitonin levels in fine needle aspiration cytology (<xref ref-type="bibr" rid="B17">17</xref>), ultrasound (<xref ref-type="bibr" rid="B2">2</xref>, <xref ref-type="bibr" rid="B18">18</xref>) and positron emission tomography/computed tomography (<xref ref-type="bibr" rid="B19">19</xref>). The second most published and most cited author, Rossella Elisei, whose main research interests were targeted therapies (<xref ref-type="bibr" rid="B20">20</xref>) and <italic>RET</italic> mutations (<xref ref-type="bibr" rid="B21">21</xref>). He was engaged in the revision of the 2015 edition of the MTC management guideline, which was responsible for its most cited authorship. His engagement in the revision of the 2015 edition of the MTC management guideline was what made him the most cited author. With the most average citations, Henning Dralle and Andreas Machens came from the same institution, and were also engaged in the revision of the 2015 edition of the MTC management guideline, their main research interests were the prognosis of MTC surgery at different stages (<xref ref-type="bibr" rid="B22">22</xref>, <xref ref-type="bibr" rid="B23">23</xref>). All of these authors were leading scholars in the field of MTC research and had played an important role in the development of the field.</p>
<p>According to Bradford&#x2019;s law, we calculated the number of core journals in the field of MTC from 2012 to 2021 to be about 8 (<xref ref-type="table" rid="T4">
<bold>Table&#xa0;4</bold>
</xref>), and the 3 most published journals were Thyroid, Endocrine, and Diagnostic cytopathology, with the most cited journal being Journal of clinical endocrinology &amp; metabolism. These journals were mostly in the field of thyroid and internal division diseases and their pathology, all of which were of great importance and influence in the field of thyroid.</p>
<p>The keyword co-occurrence map reflects the distribution of research directions in a given field over time. <xref ref-type="fig" rid="f4">
<bold>Figure&#xa0;4</bold>
</xref> revealed that the main research directions in the field of MTC research in the last 10 years had been diagnostic, non-surgical treatment, surgical treatment, genetic and related to other endocrine diseases. The table of the top 20 most important keywords (<xref ref-type="table" rid="T5">
<bold>Table&#xa0;5</bold>
</xref>) indicated that prognosis of MTC, <italic>RET</italic> gene mutations, therapeutic measures, plasma calcitonin, and interventions had been the main research features in the field of MTC in the last 10 years. Burst keywords represent the cutting-edge topics in a certain field at a certain time. The 12 burst words in <xref ref-type="fig" rid="f5">
<bold>Figure&#xa0;5</bold>
</xref> indicated that between 2012 and 2021, the research frontier in this field had gone through a total of three phases. The first phase was dominated by targeted therapies and clinical trials, the second phase, by molecular research, and the third phase, by outcome. Meanwhile outcome is also a recent research frontier in the field of MTC and a global trend in the coming years.</p>
<p>Analyzing highly cited literature helps to have a clearer understanding of the current development of a field. As shown in <xref ref-type="table" rid="T6">
<bold>Table&#xa0;6</bold>
</xref>, articles with article type review, content MTC guidelines, and targeted therapies were prone to be highly cited articles in this field. The 2015 edition of the revised MTC management guideline (<xref ref-type="bibr" rid="B5">5</xref>) states that FNAC, ultrasound, plasma calcitonin concentration, carcinoembryonic antigen values, and <italic>RET</italic> gene mutation status can be used as assists in the diagnosis of MTC. For patients without distant metastases, total thyroidectomy and dissection with or without cervical lymph nodes metastasis is the primary recommended therapy. For patients with MTC with distant metastases, treatment of the original site or systemic therapy, such as systemic therapy with tyrosine kinase inhibitors and clinical trial, can be considered. tyrosine kinase inhibitors is the most commonly used targeted therapy with MTC. In recent years, vandetanib and cabozantinib have been used to treat advanced MTC, and studies of their efficacy are gradually being conducted (<xref ref-type="bibr" rid="B24">24</xref>&#x2013;<xref ref-type="bibr" rid="B26">26</xref>). At the same time, the efficacy of other tyrosine kinase inhibitors drugs such as sunitinib in MTC is also being investigated (<xref ref-type="bibr" rid="B27">27</xref>, <xref ref-type="bibr" rid="B28">28</xref>).</p>
<p>Co-citation analysis can characterize the internal structure of knowledge based on co-cited references. <xref ref-type="fig" rid="f6">
<bold>Figure&#xa0;6</bold>
</xref> showed the top 50 cited journals among 1208 articles. These journals could be roughly divided into 4 major categories, covering endocrine-related and surgical direction, MTC pathology direction, MTC oncology, molecular. Citing these articles provided a basis for clinical interventions, facilitates a more in-depth understanding of the pathological features of MTC, and provided a basis or ideas for the exploration of tumor mechanisms.</p>
<p>This study also has some limitations. Firstly, these articles are from the Web of Science core collection of Science Citation Index Expanded and Social Sciences Citation Index. Secondly, the language of the publications is set to English and the type of the publication is set to article or review. These mentioned above may make some relevant publications missing. However, it is generally accepted that these articles represent a very small fraction of all articles and have little impact on the result of our findings (<xref ref-type="bibr" rid="B29">29</xref>). The inclusion of case reports and cases series in the bibliometric analysis could be considered in future studies, which may provide more precise hints on the direction of research at the frontiers of MTC, such as rare gene fusions and TKI therapeutic breakthroughs.</p>
<p>In general, the research of MTC is currently in a booming phase. Gene mutation, targeted therapy, mechanism and prognosis of MTC are all hot directions, and, outcome is the frontier hot spot. In the future, more related research is expected to be conducted, and research based on the above directions will become the mainstream of MTC research, which is important for the diagnosis and treatment of MTC and improving the prognosis of patients.</p>
</sec>
<sec id="s5" sec-type="conclusion">
<title>Conclusion</title>
<p>In summary, researchers had conducted numerous studies on MTC from 2012 to 2021.The United States and Italy and their institutions were leaders in MTC research, with the highest scientific productivity. Luca Giovanella was the most published author. Thyroid, Endocrine, Diagnostic cytopathology, Journal of clinical endocrinology &amp; metabolism were the most important core journals in the field. Outcome, <italic>RET</italic> gene mutations, interventions, plasma calcitonin, and targeted therapy were hot research topics in the field of MTC. Outcome was a cutting-edge topic and global trend in the field of MTC research.</p>
<p>Overall, this study is the first bibliometric analysis of MTC research. This study analyses the publications in the field of MTC and presents them in a visual way, revealing to a certain extent the development process, research hotspots and future global trends, which may provide ideas for further research.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data availability statement</title>
<p>The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.</p>
</sec>
<sec id="s7" sec-type="author-contributions">
<title>Author contributions</title>
<p>This work was conceived by RL. Data was collected and downloaded by RL, WY and ZZ. The visualization work was performed by RL. The manuscript was written by RL. XL, ZL, WY and ZZ helped to revise manuscript and proposed constructive opinions. All authors contributed to the article and approved the submitted version.</p>
</sec>
</body>
<back>
<sec id="s8" sec-type="COI-statement">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec id="s9" sec-type="disclaimer">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cabanillas</surname> <given-names>ME</given-names>
</name>
<name>
<surname>McFadden</surname> <given-names>DG</given-names>
</name>
<name>
<surname>Durante</surname> <given-names>C</given-names>
</name>
</person-group>. <article-title>Thyroid cancer</article-title>. <source>Lancet</source> (<year>2016</year>) <volume>388</volume>(<issue>10061</issue>):<page-range>2783&#x2013;95</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1016/s0140-6736(16)30172-6</pub-id>
</citation>
</ref>
<ref id="B2">
<label>2</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pereira</surname> <given-names>M</given-names>
</name>
<name>
<surname>Williams</surname> <given-names>VL</given-names>
</name>
<name>
<surname>Hallanger Johnson</surname> <given-names>J</given-names>
</name>
<name>
<surname>Valderrabano</surname> <given-names>P</given-names>
</name>
</person-group>. <article-title>Thyroid cancer incidence trends in the united states: Association with changes in professional guideline recommendations</article-title>. <source>Thyroid</source> (<year>2020</year>) <volume>30</volume>(<issue>8</issue>):<page-range>1132&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/thy.2019.0415</pub-id>
</citation>
</ref>
<ref id="B3">
<label>3</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thomas</surname> <given-names>CM</given-names>
</name>
<name>
<surname>Asa</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Ezzat</surname> <given-names>S</given-names>
</name>
<name>
<surname>Sawka</surname> <given-names>AM</given-names>
</name>
<name>
<surname>Goldstein</surname> <given-names>D</given-names>
</name>
</person-group>. <article-title>Diagnosis and pathologic characteristics of medullary thyroid carcinoma-review of current guidelines</article-title>. <source>Curr Oncol</source> (<year>2019</year>) <volume>26</volume>(<issue>5</issue>):<page-range>338&#x2013;44</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.3747/co.26.5539</pub-id>
</citation>
</ref>
<ref id="B4">
<label>4</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Raue</surname> <given-names>F</given-names>
</name>
<name>
<surname>Frank-Raue</surname> <given-names>K</given-names>
</name>
</person-group>. <article-title>Long-term follow-up in medullary thyroid carcinoma</article-title>. <source>Recent Results Cancer Res</source> (<year>2015</year>) <volume>204</volume>:<page-range>207&#x2013;25</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/978-3-319-22542-5_10</pub-id>
</citation>
</ref>
<ref id="B5">
<label>5</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wells</surname> <given-names>SA</given-names>
<suffix>Jr.</suffix>
</name>
<name>
<surname>Asa</surname> <given-names>SL</given-names>
</name>
<name>
<surname>Dralle</surname> <given-names>H</given-names>
</name>
<name>
<surname>Elisei</surname> <given-names>R</given-names>
</name>
<name>
<surname>Evans</surname> <given-names>DB</given-names>
</name>
<name>
<surname>Gagel</surname> <given-names>RF</given-names>
</name>
<etal/>
</person-group>. <article-title>Revised American thyroid association guidelines for the management of medullary thyroid carcinoma</article-title>. <source>Thyroid</source> (<year>2015</year>) <volume>25</volume>(<issue>6</issue>):<fpage>567</fpage>&#x2013;<lpage>610</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1089/thy.2014.0335</pub-id>
</citation>
</ref>
<ref id="B6">
<label>6</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Feng</surname> <given-names>C</given-names>
</name>
<name>
<surname>Tian</surname> <given-names>C</given-names>
</name>
<name>
<surname>Huang</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Feng</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Chang</surname> <given-names>S</given-names>
</name>
</person-group>. <article-title>A bibliometric analysis of the landscape of parathyroid carcinoma research based on the pubmed (2000-2021)</article-title>. <source>Front Oncol</source> (<year>2022</year>) <volume>12</volume>:<elocation-id>824201</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2022.824201</pub-id>
</citation>
</ref>
<ref id="B7">
<label>7</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Leng</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Fang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>M</given-names>
</name>
<name>
<surname>Li</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Kang</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Global research trend of esophageal squamous cell carcinoma from 2012 to 2022: A bibliometric analysis</article-title>. <source>Front Oncol</source> (<year>2022</year>) <volume>12</volume>:<elocation-id>977935</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2022.977935</pub-id>
</citation>
</ref>
<ref id="B8">
<label>8</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chen</surname> <given-names>K</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>Z</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>W</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>D</given-names>
</name>
<name>
<surname>Zhang</surname> <given-names>T</given-names>
</name>
<name>
<surname>He</surname> <given-names>L</given-names>
</name>
<etal/>
</person-group>. <article-title>Bibliometric insights in advances of papillary thyroid microcarcinoma: Research situation, hot points, and global trends</article-title>. <source>Front Endocrinol (Lausanne)</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>949993</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fendo.2022.949993</pub-id>
</citation>
</ref>
<ref id="B9">
<label>9</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname> <given-names>H</given-names>
</name>
<name>
<surname>Yu</surname> <given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname> <given-names>K</given-names>
</name>
<name>
<surname>Sun</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Bibliometric insights in advances of anaplastic thyroid cancer: Research landscapes, turning points, and global trends</article-title>. <source>Front Oncol</source> (<year>2021</year>) <volume>11</volume>:<elocation-id>769807</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2021.769807</pub-id>
</citation>
</ref>
<ref id="B10">
<label>10</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Su</surname> <given-names>J</given-names>
</name>
<name>
<surname>Gao</surname> <given-names>G</given-names>
</name>
<name>
<surname>Xu</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Bibliometric analysis of research on thyroid ultrasonography</article-title>. <source>Gland Surg</source> (<year>2021</year>) <volume>10</volume>(<issue>12</issue>):<page-range>3283&#x2013;93</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.21037/gs-21-799</pub-id>
</citation>
</ref>
<ref id="B11">
<label>11</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Falagas</surname> <given-names>ME</given-names>
</name>
<name>
<surname>Pitsouni</surname> <given-names>EI</given-names>
</name>
<name>
<surname>Malietzis</surname> <given-names>GA</given-names>
</name>
<name>
<surname>Pappas</surname> <given-names>G</given-names>
</name>
</person-group>. <article-title>Comparison of pubmed, scopus, web of science, and Google scholar: Strengths and weaknesses</article-title>. <source>FASEB J</source> (<year>2008</year>) <volume>22</volume>(<issue>2</issue>):<page-range>338&#x2013;42</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1096/fj.07-9492LSF</pub-id>
</citation>
</ref>
<ref id="B12">
<label>12</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>van Eck</surname> <given-names>NJ</given-names>
</name>
<name>
<surname>Waltman</surname> <given-names>L</given-names>
</name>
</person-group>. <article-title>Software survey: Vosviewer, a computer program for bibliometric mapping</article-title>. <source>Scientometrics</source> (<year>2010</year>) <volume>84</volume>(<issue>2</issue>):<page-range>523&#x2013;38</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s11192-009-0146-3</pub-id>
</citation>
</ref>
<ref id="B13">
<label>13</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Synnestvedt</surname> <given-names>MB</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>C</given-names>
</name>
<name>
<surname>Holmes</surname> <given-names>JH</given-names>
</name>
</person-group>. <article-title>Citespace ii: Visualization and knowledge discovery in bibliographic databases</article-title>. <source>AMIA Annu Symp Proc</source> (<year>2005</year>) <volume>2005</volume>:<page-range>724&#x2013;8</page-range>.</citation>
</ref>
<ref id="B14">
<label>14</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<collab>Bradford</collab>
</person-group>. <article-title>Sources of information on specific subjects</article-title>. <source>Engineering</source> (<year>1934</year>) <volume>23</volume>:<fpage>3</fpage>.</citation>
</ref>
<ref id="B15">
<label>15</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trimboli</surname> <given-names>P</given-names>
</name>
<name>
<surname>Giovanella</surname> <given-names>L</given-names>
</name>
<name>
<surname>Crescenzi</surname> <given-names>A</given-names>
</name>
<name>
<surname>Romanelli</surname> <given-names>F</given-names>
</name>
<name>
<surname>Valabrega</surname> <given-names>S</given-names>
</name>
<name>
<surname>Spriano</surname> <given-names>G</given-names>
</name>
<etal/>
</person-group>. <article-title>Medullary thyroid cancer diagnosis: An appraisal</article-title>. <source>Head Neck</source> (<year>2014</year>) <volume>36</volume>(<issue>8</issue>):<page-range>1216&#x2013;23</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1002/hed.23449</pub-id>
</citation>
</ref>
<ref id="B16">
<label>16</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trimboli</surname> <given-names>P</given-names>
</name>
<name>
<surname>Treglia</surname> <given-names>G</given-names>
</name>
<name>
<surname>Guidobaldi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Romanelli</surname> <given-names>F</given-names>
</name>
<name>
<surname>Nigri</surname> <given-names>G</given-names>
</name>
<name>
<surname>Valabrega</surname> <given-names>S</given-names>
</name>
<etal/>
</person-group>. <article-title>Detection rate of fna cytology in medullary thyroid carcinoma: A meta-analysis</article-title>. <source>Clin Endocrinol (Oxf)</source> (<year>2015</year>) <volume>82</volume>(<issue>2</issue>):<page-range>280&#x2013;5</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/cen.12563</pub-id>
</citation>
</ref>
<ref id="B17">
<label>17</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trimboli</surname> <given-names>P</given-names>
</name>
<name>
<surname>Cremonini</surname> <given-names>N</given-names>
</name>
<name>
<surname>Ceriani</surname> <given-names>L</given-names>
</name>
<name>
<surname>Saggiorato</surname> <given-names>E</given-names>
</name>
<name>
<surname>Guidobaldi</surname> <given-names>L</given-names>
</name>
<name>
<surname>Romanelli</surname> <given-names>F</given-names>
</name>
<etal/>
</person-group>. <article-title>Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: A retrospective multicentre study</article-title>. <source>Clin Endocrinol (Oxf)</source> (<year>2014</year>) <volume>80</volume>(<issue>1</issue>):<page-range>135&#x2013;40</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1111/cen.12234</pub-id>
</citation>
</ref>
<ref id="B18">
<label>18</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Trimboli</surname> <given-names>P</given-names>
</name>
<name>
<surname>Giovanella</surname> <given-names>L</given-names>
</name>
<name>
<surname>Valabrega</surname> <given-names>S</given-names>
</name>
<name>
<surname>Andrioli</surname> <given-names>M</given-names>
</name>
<name>
<surname>Baldelli</surname> <given-names>R</given-names>
</name>
<name>
<surname>Cremonini</surname> <given-names>N</given-names>
</name>
<etal/>
</person-group>. <article-title>Ultrasound features of medullary thyroid carcinoma correlate with cancer aggressiveness: A retrospective multicenter study</article-title>. <source>J Exp Clin Cancer Res</source> (<year>2014</year>) <volume>33</volume>(<issue>1</issue>):<elocation-id>87</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.1186/s13046-014-0087-4</pub-id>
</citation>
</ref>
<ref id="B19">
<label>19</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Giovanella</surname> <given-names>L</given-names>
</name>
<name>
<surname>Treglia</surname> <given-names>G</given-names>
</name>
<name>
<surname>Iakovou</surname> <given-names>I</given-names>
</name>
<name>
<surname>Mihailovic</surname> <given-names>J</given-names>
</name>
<name>
<surname>Verburg</surname> <given-names>FA</given-names>
</name>
<name>
<surname>Luster</surname> <given-names>M</given-names>
</name>
</person-group>. <article-title>Eanm practice guideline for Pet/Ct imaging in medullary thyroid carcinoma</article-title>. <source>Eur J Nucl Med Mol Imaging</source> (<year>2020</year>) <volume>47</volume>(<issue>1</issue>):<fpage>61</fpage>&#x2013;<lpage>77</lpage>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s00259-019-04458-6</pub-id>
</citation>
</ref>
<ref id="B20">
<label>20</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elisei</surname> <given-names>R</given-names>
</name>
<name>
<surname>Schlumberger</surname> <given-names>MJ</given-names>
</name>
<name>
<surname>M&#xfc;ller</surname> <given-names>SP</given-names>
</name>
<name>
<surname>Sch&#xf6;ffski</surname> <given-names>P</given-names>
</name>
<name>
<surname>Brose</surname> <given-names>MS</given-names>
</name>
<name>
<surname>Shah</surname> <given-names>MH</given-names>
</name>
<etal/>
</person-group>. <article-title>Cabozantinib in progressive medullary thyroid cancer</article-title>. <source>J Clin Oncol</source> (<year>2013</year>) <volume>31</volume>(<issue>29</issue>):<page-range>3639&#x2013;46</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1200/jco.2012.48.4659</pub-id>
</citation>
</ref>
<ref id="B21">
<label>21</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elisei</surname> <given-names>R</given-names>
</name>
<name>
<surname>Romei</surname> <given-names>C</given-names>
</name>
<name>
<surname>Renzini</surname> <given-names>G</given-names>
</name>
<name>
<surname>Bottici</surname> <given-names>V</given-names>
</name>
<name>
<surname>Cosci</surname> <given-names>B</given-names>
</name>
<name>
<surname>Molinaro</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>The timing of total thyroidectomy in ret gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center</article-title>. <source>J Clin Endocrinol Metab</source> (<year>2012</year>) <volume>97</volume>(<issue>2</issue>):<page-range>426&#x2013;35</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1210/jc.2011-2046</pub-id>
</citation>
</ref>
<ref id="B22">
<label>22</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Machens</surname> <given-names>A</given-names>
</name>
<name>
<surname>Dralle</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Prognostic impact of n staging in 715 medullary thyroid cancer patients: Proposal for a revised staging system</article-title>. <source>Ann Surg</source> (<year>2013</year>) <volume>257</volume>(<issue>2</issue>):<page-range>323&#x2013;9</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/SLA.0b013e318268301d</pub-id>
</citation>
</ref>
<ref id="B23">
<label>23</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brauckhoff</surname> <given-names>M</given-names>
</name>
<name>
<surname>Machens</surname> <given-names>A</given-names>
</name>
<name>
<surname>Lorenz</surname> <given-names>K</given-names>
</name>
<name>
<surname>Bj&#xf8;ro</surname> <given-names>T</given-names>
</name>
<name>
<surname>Varhaug</surname> <given-names>JE</given-names>
</name>
<name>
<surname>Dralle</surname> <given-names>H</given-names>
</name>
</person-group>. <article-title>Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2b: A changing perspective</article-title>. <source>Ann Surg</source> (<year>2014</year>) <volume>259</volume>(<issue>4</issue>):<page-range>800&#x2013;6</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1097/SLA.0b013e3182a6f43a</pub-id>
</citation>
</ref>
<ref id="B24">
<label>24</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Brandenburg</surname> <given-names>T</given-names>
</name>
<name>
<surname>Tiedje</surname> <given-names>V</given-names>
</name>
<name>
<surname>Muchalla</surname> <given-names>P</given-names>
</name>
<name>
<surname>Theurer</surname> <given-names>S</given-names>
</name>
<name>
<surname>Weber</surname> <given-names>F</given-names>
</name>
<name>
<surname>Schmid</surname> <given-names>KW</given-names>
</name>
<etal/>
</person-group>. <article-title>Continued discontinuation of tki treatment in medullary thyroid carcinoma - lessons from individual cases with long-term follow-up</article-title>. <source>Front Endocrinol (Lausanne)</source> (<year>2021</year>) <volume>12</volume>:<elocation-id>718418</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fendo.2021.718418</pub-id>
</citation>
</ref>
<ref id="B25">
<label>25</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Scirocchi</surname> <given-names>F</given-names>
</name>
<name>
<surname>Napoletano</surname> <given-names>C</given-names>
</name>
<name>
<surname>Pace</surname> <given-names>A</given-names>
</name>
<name>
<surname>Rahimi Koshkaki</surname> <given-names>H</given-names>
</name>
<name>
<surname>Di Filippo</surname> <given-names>A</given-names>
</name>
<name>
<surname>Zizzari</surname> <given-names>IG</given-names>
</name>
<etal/>
</person-group>. <article-title>Immunogenic cell death and immunomodulatory effects of cabozantinib</article-title>. <source>Front Oncol</source> (<year>2021</year>) <volume>11</volume>:<elocation-id>755433</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fonc.2021.755433</pub-id>
</citation>
</ref>
<ref id="B26">
<label>26</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nagilla</surname> <given-names>M</given-names>
</name>
<name>
<surname>Brown</surname> <given-names>RL</given-names>
</name>
<name>
<surname>Cohen</surname> <given-names>EE</given-names>
</name>
</person-group>. <article-title>Cabozantinib for the treatment of advanced medullary thyroid cancer</article-title>. <source>Adv Ther</source> (<year>2012</year>) <volume>29</volume>(<issue>11</issue>):<page-range>925&#x2013;34</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s12325-012-0060-6</pub-id>
</citation>
</ref>
<ref id="B27">
<label>27</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ferrari</surname> <given-names>SM</given-names>
</name>
<name>
<surname>Centanni</surname> <given-names>M</given-names>
</name>
<name>
<surname>Virili</surname> <given-names>C</given-names>
</name>
<name>
<surname>Miccoli</surname> <given-names>M</given-names>
</name>
<name>
<surname>Ferrari</surname> <given-names>P</given-names>
</name>
<name>
<surname>Ruffilli</surname> <given-names>I</given-names>
</name>
<etal/>
</person-group>. <article-title>Sunitinib in the treatment of thyroid cancer</article-title>. <source>Curr Med Chem</source> (<year>2019</year>) <volume>26</volume>(<issue>6</issue>):<page-range>963&#x2013;72</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.2174/0929867324666171006165942</pub-id>
</citation>
</ref>
<ref id="B28">
<label>28</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Matrone</surname> <given-names>A</given-names>
</name>
<name>
<surname>Prete</surname> <given-names>A</given-names>
</name>
<name>
<surname>Nervo</surname> <given-names>A</given-names>
</name>
<name>
<surname>Ragni</surname> <given-names>A</given-names>
</name>
<name>
<surname>Agate</surname> <given-names>L</given-names>
</name>
<name>
<surname>Molinaro</surname> <given-names>E</given-names>
</name>
<etal/>
</person-group>. <article-title>Lenvatinib as a salvage therapy for advanced metastatic medullary thyroid cancer</article-title>. <source>J Endocrinol Invest</source> (<year>2021</year>) <volume>44</volume>(<issue>10</issue>):<page-range>2139&#x2013;51</page-range>. doi:&#xa0;<pub-id pub-id-type="doi">10.1007/s40618-020-01491-3</pub-id>
</citation>
</ref>
<ref id="B29">
<label>29</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Shen</surname> <given-names>H</given-names>
</name>
<name>
<surname>Ke</surname> <given-names>L</given-names>
</name>
<name>
<surname>Chen</surname> <given-names>J</given-names>
</name>
<name>
<surname>Dang</surname> <given-names>X</given-names>
</name>
<name>
<surname>Liu</surname> <given-names>B</given-names>
</name>
<etal/>
</person-group>. <article-title>Knowledge mapping of immunotherapy for hepatocellular carcinoma: A bibliometric study</article-title>. <source>Front Immunol</source> (<year>2022</year>) <volume>13</volume>:<elocation-id>815575</elocation-id>. doi:&#xa0;<pub-id pub-id-type="doi">10.3389/fimmu.2022.815575</pub-id>
</citation>
</ref>
</ref-list>
</back>
</article>